Profiles

Keywords
Last Name
Institution

Connection

John Somberg to United States Food and Drug Administration

This is a "connection" page, showing publications John Somberg has written about United States Food and Drug Administration.

 
Connection Strength
 
 
 
6.520
 
  1. Somberg JC. Drug shortages and ensuring the U.S. supply of needed pharmaceuticals. Am J Ther. 2012 Mar; 19(2):65.
    View in: PubMed
    Score: 0.548
  2. Somberg JC. Has the food and drug administration changed the drug approval process? Am J Ther. 2011 May; 18(3):179.
    View in: PubMed
    Score: 0.517
  3. Somberg J. FDA user fees and innovation. Am J Ther. 2008 Mar-Apr; 15(2):97.
    View in: PubMed
    Score: 0.415
  4. Somberg J. Patent foramen ovale closure devices: thoughts from the circulatory device advisory panel. Am J Cardiol. 2007 Sep 01; 100(5):905-6.
    View in: PubMed
    Score: 0.395
  5. Somberg J. The drug safety review process. Am J Ther. 2007 Mar-Apr; 14(2):119.
    View in: PubMed
    Score: 0.387
  6. Somberg J. The report of the Institute of Medicine on drug safety. Am J Ther. 2007 Jan-Feb; 14(1):1-2.
    View in: PubMed
    Score: 0.383
  7. Somberg JC. An opportunity to distance the FDA from Washington politics. Am J Ther. 2005 Nov-Dec; 12(6):475.
    View in: PubMed
    Score: 0.353
  8. Somberg J. The provisional approval step. Am J Ther. 2005 Jan-Feb; 12(1):1-2.
    View in: PubMed
    Score: 0.333
  9. Somberg JC. Restricting physician prescribing. Am J Ther. 2002 Sep-Oct; 9(5):369.
    View in: PubMed
    Score: 0.283
  10. Somberg JC. Are we overregulated? Am J Ther. 2001 Jan-Feb; 8(1):1-2.
    View in: PubMed
    Score: 0.253
  11. Somberg JC, McEwen P, Molnar J. Assessment of cardiovascular and noncardiovascular medical device recalls. Am J Cardiol. 2014 Jun 01; 113(11):1899-903.
    View in: PubMed
    Score: 0.158
  12. Somberg J. The conflict of interest charade. Am J Ther. 2013 Nov-Dec; 20(6):591.
    View in: PubMed
    Score: 0.154
  13. Somberg JC. Proposed accelerated FDA approvals for special medical use. Am J Ther. 2012 Nov; 19(6):393-4.
    View in: PubMed
    Score: 0.143
  14. Somberg JC. Sharing regulatory review costs. J Clin Pharmacol. 1992 Oct; 32(10):867.
    View in: PubMed
    Score: 0.143
  15. Somberg JC. Making America more competitive: a paradigm shift in drug and device development. Am J Ther. 2012 Sep; 19(5):315-6.
    View in: PubMed
    Score: 0.142
  16. Somberg JC. The device development pinata. Am J Ther. 2011 Sep; 18(5):339.
    View in: PubMed
    Score: 0.132
  17. Somberg JC. Inappropriate attack on device development. Am J Ther. 2011 Mar-Apr; 18(2):91.
    View in: PubMed
    Score: 0.128
  18. Somberg JC. The Food and Drug Administration's paternalism. Am J Ther. 2010 Nov-Dec; 17(6):533-4.
    View in: PubMed
    Score: 0.125
  19. Somberg JC, Preston RA, Ranade V, Molnar J. Developing a safe intravenous sotalol dosing regimen. Am J Ther. 2010 Jul-Aug; 17(4):365-72.
    View in: PubMed
    Score: 0.122
  20. Somberg J. Device safety and effectiveness. Am J Ther. 2010 Jul-Aug; 17(4):357.
    View in: PubMed
    Score: 0.122
  21. Somberg JC. The extrapolation of study results in the device approval process. Am J Cardiol. 2009 May 01; 103(9):1323-4.
    View in: PubMed
    Score: 0.111
  22. Somberg JC. Securing the US pharmaceutical supply. Am J Ther. 2008 May-Jun; 15(3):197.
    View in: PubMed
    Score: 0.105
  23. Somberg J. Mandatory post marketing studies. Am J Ther. 2007 Jul-Aug; 14(4):321.
    View in: PubMed
    Score: 0.099
  24. Somberg J. Off-label promotion. Am J Ther. 2006 Sep-Oct; 13(5):387.
    View in: PubMed
    Score: 0.094
  25. Somberg JC. Nesiritide: the wrong controversy. Am J Ther. 2005 Sep-Oct; 12(5):377-8.
    View in: PubMed
    Score: 0.087
  26. Somberg J. Lessons learned from the COX-2 advisory hearings. Am J Ther. 2005 Mar-Apr; 12(2):105.
    View in: PubMed
    Score: 0.084
  27. Somberg J. The politics of therapeutics. Am J Ther. 2004 Nov-Dec; 11(6):422.
    View in: PubMed
    Score: 0.082
  28. Somberg J. Drug trial registries. Am J Ther. 2004 Sep-Oct; 11(5):327.
    View in: PubMed
    Score: 0.081
  29. Somberg J. Should statins go OTC. Am J Ther. 2004 Jan-Feb; 11(1):1-2.
    View in: PubMed
    Score: 0.078
  30. Somberg J. Therapeutics, drug pricing and innovation. Am J Ther. 2003 Nov-Dec; 10(6):381.
    View in: PubMed
    Score: 0.077
  31. Somberg J. Clinical trials registries. Am J Ther. 2003 Sep-Oct; 10(5):309-10.
    View in: PubMed
    Score: 0.076
  32. Somberg JC. Old drugs, new bottles, therapeutic advantage? Am J Ther. 2002 Jul-Aug; 9(4):273-4.
    View in: PubMed
    Score: 0.070
  33. Somberg JC. Proposed product labeling changes: does it really matter? Am J Ther. 2001 May-Jun; 8(3):145-6.
    View in: PubMed
    Score: 0.065
  34. Somberg JC. Adverse drug reaction reporting. Am J Ther. 2000 Aug; 7(4):227-8.
    View in: PubMed
    Score: 0.061
  35. Somberg JC. Medical judgment and therapeutics. Am J Ther. 1999 Nov; 6(6):291-2.
    View in: PubMed
    Score: 0.058
  36. Somberg JC, Borer JS. Advances in cardiovascular pharmacology: protocol design and methodology--the US regulatory process. Am J Ther. 1999 May; 6(3):175-8.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.